Former Teva exec named general manager of Stada Arz' Italian affiliate
German drugmaker Stada Arzneimittel (SAZ: Xetra) has nominated a successor for Enrique Häusermann, the long-time general manager of its Italian unit EG SpA.
Salvatore Butti will take over the operations of Stada’s Italian affiliate at September 1, 2019. Mr Häusermann will continue to support as member of the company’s Italian supervisory board.
Salvatori Butti has more than 35 years of experience in the pharmaceutical industry. He will join EuroGenerici from Teva Italy, where he held the position of senior director Generics, OTC and Portfolio since 2013. In the course of his career Mr Butti also held various leadership positions in pharmaceutical companies, eg, at Sanofi Aventis SpA and Recordati SpA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze